Life Sciences
OrbiMed Secures $4.3B to Invest in Healthcare Startups Globally
What You Should Know: – OrbiMed, a global healthcare investment firm raises $4.3B in commitments across its four investment funds: OrbiMed Private Investments…
What You Should Know:
– OrbiMed, a global healthcare investment firm raises $4.3B in commitments across its four investment funds: OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV.
– The $4.3B will be used to invest globally, from the seed stage for start-ups incubated by OrbiMed through growth capital opportunities. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
Investment Thesis
OrbiMed works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing. OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.
“OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds,” said Carter Neild, a Managing Partner of OrbiMed. “We will endeavor to meet our partners’ high expectations in the coming years.”
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….